MetaCap

Grifols S.A. (GRFS) vs Veradermics (MANE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Grifols S.A. is the larger company by market cap ($5.55 billion vs $5.04 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRFS-14.57%MANE+216.61%
+332%+144%-43%
Feb 4, 20261 yearNov 20, 2026
GRFS-12.18%MANE+210.60%
+277%+120%-37%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRFS versus MANE key metrics
MetricGRFSMANE
Share price$8.15$119.52
Market cap$5.55B$5.04B
1-day change-0.61%-3.92%
YTD return-12.83%—
1-year return-2.98%—
5-year return-25.30%—
P/E ratio (TTM)9.82—
Forward P/E6.55—
EPS (TTM)$0.83$-3.89
Dividend yield1.30%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-70.00M
52-week high$9.77$156.63
52-week low$6.96$32.00
Distance from 52-week high-16.58%-23.69%
Analyst consensusbuystrong_buy
Avg. price target upside+27.24%+56.74%
Average volume628.64K738.22K
Shares outstanding258.22M42.20M
Employees25,00051
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).

About Grifols S.A.

GRFS stock →

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees

About Veradermics

MANE stock →

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

GRFS vs MANE FAQ

Which is bigger, Grifols S.A. or Veradermics?

Grifols S.A. (GRFS) is larger, with a market capitalization of $5.55B compared with $5.04B for Veradermics (MANE).

Which pays a higher dividend, Grifols S.A. or Veradermics?

Grifols S.A. pays a dividend yielding 1.30%, while Veradermics does not currently pay a regular dividend.

Are Grifols S.A. and Veradermics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons